Loading…
← CockpitCompetitor Analysis › 603676.SS Xizang Weixinkang Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Xizang Weixinkang Pharmaceutical Co., Ltd. Class A603676.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum neutral 56
Mkt cap
$513M
US dollars, full cap
Free float
32%
of shares outstanding
$/day
$2.40M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+22.7 pp
WACC 5.0%
Hurdle
-16 pp
Req g minus delivered
Next earnings
156 days
23 Apr 2027
Close · CNYCN¥7.87
1D-2.5%
1W-4.7%
1M-9.5%
3M-15.2%
6M-21.8%
YTD-25.2%
1Y-29.2%
ATR %2.7%
52w lowhigh33.8% off high

What Xizang Weixinkang Pharmaceutical does

Employees: 763

Xizang Weixinkang Pharmaceutical at a glance

Size Xizang Weixinkang Pharmaceutical (603676.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $513M, the 3636th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥7.87 on 18 Nov 2026.

Performance Over six months the shares fell 21.8%, against -18.4% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 19 in its peer set.

Growth Revenue fell 8.3% over the last twelve months (peer median +9.6%); the operating margin is 16.1% (peer median 11.2%).

Valuation It trades at 2.3× enterprise value to sales against a peer median of 4.4× (6th cheapest of 19).

Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -16 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 22.7 points above its cost of capital (5.0% WACC).

Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026Peer median 83603676.SS 80
Six months, rebased to 100: Xizang Weixinkang Pharmaceutical against the median of its 20 peers (local-currency closes).

Xizang Weixinkang Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.07BCN¥1.12BCN¥1.29BCN¥1.31BCN¥1.39B
Revenue growth—-13%-2%-5%—
Gross profitCN¥640MCN¥654MCN¥658MCN¥618MCN¥686M
EBITDAn/aCN¥269MCN¥281MCN¥194MCN¥208M
Net incomeCN¥190MCN¥233MCN¥246MCN¥214MCN¥177M
Free cash flowCN¥157MCN¥123MCN¥339MCN¥186MCN¥184M
Capital expenditureCN¥90.2MCN¥83.9MCN¥58.2MCN¥70.8MCN¥77.7M
Total debtCN¥9.45MCN¥11.2MCN¥5.27MCN¥30.1MCN¥29.6M

Quarterly statements and history in the cockpit →

Xizang Weixinkang Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-20%0%+20%EGTX300485INDPGUJTHEM603207GYRESUPRIYA600222TKNO600513003090AARTIDRUGS0021071666SENORES603676.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Xizang Weixinkang Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×25×50×75×EGTX300485GUJTHEM603207GYREEVONILESUPRIYA000919600222TKNO6005130030906032220021071666SENORES603676.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Xizang Weixinkang Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-20%0%20%40%603207EVONILESUPRIYA000919600222AARTIDRUGS0021071666301277603676.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Xizang Weixinkang Pharmaceutical is the large dot.

Xizang Weixinkang Pharmaceutical competitors and peer comparison

How Xizang Weixinkang Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Xizang Weixinkang Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure603676.SSPeer medianRank in peer set
1-month return-9.5%-7.0%9th lowest of 20
6-month return-21.8%-18.4%7th lowest of 19
Distance from 52-week high-33.8%-39.7%7th highest of 20
Revenue growth (TTM)-8.3%+9.6%3rd lowest of 19
Operating margin16.1%11.2%6th highest of 19
EV / Sales2.3×4.4×6th cheapest of 19
Growth the price implies (Req g, 7 yrs)-6.1%8.9%2nd least demanding of 10
Growth delivered (Del g)+9.6%+5.0%2nd highest of 10
Hurdle (Req g minus delivered)-15.7 pp+10.0 pp2nd least demanding of 10
ROIC minus cost of capital+22.7 pp-2.7 pp3rd highest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Xizang Weixinkang Pharmaceutical 603676.SSChina$513M-22%-8%16%2.3×-6.1%+9.6%
Egetis Therapeutics EGTX.STSweden$509M+76%+27%-645%71.0×n/an/a
Beijing Science Sun Pharmaceutical 300485.SZChina$517M-29%-11%-8%5.6×n/an/a
Indaptus Therapeutics INDPUnited States$505M+147%n/an/an/an/an/a
Gujarat Themis Biosyn GUJTHEM.NSIndia$505M+2%+18%39%27.2×n/an/a
Shanghai Xiao Fang Pharmaceutical 603207.SSChina$503M-17%+10%39%4.8×-5.4%+7.6%
Gyre Therapeutics GYREUnited States$500M-28%+14%-18%4.0×n/an/a
Evonile Pharma EVONILE.NSIndia$529Mn/a-5%12%16.2×49.3%-1.5%
Supriya Lifescience SUPRIYA.NSIndia$529M-15%+23%26%5.5×28.2%+15.8%
Jinling Pharmaceutical 000919.SZChina$529M-15%-8%1%0.7×2.4%+5.0%
Henan Taloph Pharmaceutical Stock 600222.SSChina$497M-21%-5%7%2.5×16.7%+4.4%
Electra Therapeutics ETRAUnited States$530Mn/an/an/an/an/an/a
Alpha Teknova TKNOUnited States$496M+113%+15%-32%11.0×n/an/a
Jiangsu Lianhuan Pharmaceutical 600513.SSChina$496M-41%+14%0%1.8×n/an/a
Daewoong 003090.KSSouth Korea$495M-28%+6%11%0.9×n/an/a
Aarti Drugs AARTIDRUGS.NSIndia$494M+34%+15%11%1.8×22.1%+3.5%
Chimin Health Management 603222.SSChina$533M-31%+1%-28%6.6×n/an/a
Shandong Wohua Pharmaceutical 002107.SZChina$493M-20%-4%18%3.7×5.9%-4.1%
Tong Ren Tang Technologies 1666.HKHong Kong$491M-19%-14%12%0.6×-17.2%+6.3%
Senores Pharmaceuticals SENORES.NSIndia$538M+3%+40%24%7.4×n/an/a
Newland Pharmaceutical 301277.SZChina$488M-22%+9%11%3.5×8.9%+9.1%

Questions

Which companies are Xizang Weixinkang Pharmaceutical's closest peers?
The cockpit's peer set: Egetis Therapeutics (EGTX.ST), Beijing Science Sun Pharmaceutical (300485.SZ), Indaptus Therapeutics (INDP), Gujarat Themis Biosyn (GUJTHEM.NS), Shanghai Xiao Fang Pharmaceutical (603207.SS), Gyre Therapeutics (GYRE), Evonile Pharma (EVONILE.NS), Supriya Lifescience (SUPRIYA.NS).
Is Xizang Weixinkang Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 2.3× against a peer median of 4.4×, 6th cheapest of 19 in its peer set. For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -16 pp: the price already allows for a slowdown.
How has Xizang Weixinkang Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -21.8% against -18.4% for the median peer; over one year -29.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.